Skip to content
SurenoGet Sureno Browser
← Sureno News

China’s Closely Watched Lung Cancer Drug Faces F.D.A. Rejection Despite Delaying Progression

A setback for Summit

The Food and Drug Administration turned down ivonescimab, a drug invented in China. The decision challenges a treatment that had come to represent China’s expanding influence in developing medicines.

Summit had sought approval for the drug for certain patients with advanced lung cancer. Its wider testing in colon, bladder and breast tumors had helped fuel interest beyond that initial use.

Trial showed delayed progression

Summit’s application relied on a study conducted across the United States, Canada, Europe and Asia. It enrolled patients who had already received a targeted treatment and compared ivonescimab plus chemotherapy with chemotherapy alone.

Extra analyses fell short

Summit said the lack of a survival benefit reflected the study’s slow enrollment. The company also provided regulators with analyses of longer-term patient outcomes that had not been laid out in the original research plan.

Key points

  • The F.D.A. rejected ivonescimab, developed in China, for certain advanced lung cancer patients.
  • The trial found that ivonescimab with chemotherapy delayed cancer progression.
  • The study did not show that patients lived longer.
  • The drug is being tested in colon, bladder and breast cancers.
Read the original on nytimes.com ↗

More news

Loading stories…